TB Alliance | PAN-TB Collaboration to Launch New Clinical Trial of Next-Generation TB Treatment Regimen
10 November 2026
TB Alliance news release
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) Collaboration announced plans to launch a Phase 2 clinical trial evaluating a novel four-drug regimen designed to shorten treatment for drug-sensitive TB from six months to four. Enrollment is expected to begin in the third quarter of 2027 at trial sites across Africa and Asia.
The trial will include two new investigational compounds, TBD09 and TBD11, initially advanced through the TB Drug Accelerator and now being developed by the Gates Medical Research Institute. The regimen also includes two compounds from TB Alliance: sorfequiline, an investigational compound currently in Phase 2 for the treatment of drug-sensitive TB and pretomanid, which is recommended by the World Health Organization to treat rifampicin-resistant/multidrug-resistant TB as part of the bedaquiline, pretomanid and linezolid (BPaL) regimen, except in certain circumstances. Together, the four compounds combine different mechanisms of action which could potentially shorten the treatment course.
Read the full news release here.
Source: TB Alliance
